Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 301 | Eisai Inc.INDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT07491159 | Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study | active not recruiting | Phase 1 / Phase 2 | 106 | Tianjin Medical University Cancer Institute and HospitalOTHER |
| 1 |
| Mar 24, 2026 |
| clinicaltrials |
| NCT03654131 | Microwave Ablation Versus Stereotactic Body Radiotherapy for Colorectal Liver Metastases in Oligometastatic Disease: a Prospective, Randomised, Phase 2 Trial(LAVA-CRLM) | active not recruiting | Phase 2 | 100 | Rigshospitalet, DenmarkOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04699188 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-01) | active not recruiting | Phase 1 / Phase 2 | 344 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT05194995 | JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation | active not recruiting | Phase 1 / Phase 2 | 48 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06256328 | A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) | active not recruiting | Phase 2 | 226 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | Mar 13, 2026 | clinicaltrials |
| NCT06646055 | AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 110 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04563338 | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | active not recruiting | Phase 2 | 36 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05846867 | A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 170 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05078866 | Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients | active not recruiting | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | Mar 3, 2026 | clinicaltrials |
| NCT03403465 | Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers | active not recruiting | Phase 2 | 90 | Duke UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04969887 | Combination Immunotherapy in Rare Cancers Under InvesTigation(MOST-CIRCUIT) | active not recruiting | Phase 2 | 240 | Olivia Newton-John Cancer Research InstituteOTHER | 2 | Feb 27, 2026 | clinicaltrials |
| NCT05642962 | Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) | active not recruiting | Phase 1 / Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04430738 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | active not recruiting | Phase 2 | 40 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT05438420 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Qurient Co., Ltd.INDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT06178588 | Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma | active not recruiting | Phase 2 | 15 | University of Kansas Medical CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06356597 | Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial | active not recruiting | Phase 2 | 33 | Jing-yuan Fang, MD, Ph. DOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT03174275 | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | active not recruiting | Phase 1 / Phase 2 | 194 | Merus B.V.INDUSTRY | 9 | Feb 19, 2026 | clinicaltrials |
| NCT05466799 | FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma(TRIPP-FFX) | active not recruiting | Phase 2 | 88 | OncoSil Medical LimitedINDUSTRY | 5 | Feb 13, 2026 | clinicaltrials |
| NCT05451290 | Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer | active not recruiting | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05673772 | Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer(SOLAR) | active not recruiting | Phase 2 | 364 | Kyungpook National University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT01815359 | ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis(ICARuS) | active not recruiting | Phase 2 | 292 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT06268015 | Botensilimab and Balstilimab Optimization in Colorectal Cancer(BBOpCo) | active not recruiting | Phase 2 | 16 | Nicholas DeVito, MDOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04762953 | Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis(STOPGAP) | active not recruiting | Phase 2 | 40 | University of California, IrvineOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05621707 | Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)(RICE) | active not recruiting | Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT07380633 | Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial | active not recruiting | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05113186 | Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative(LENVABLA) | active not recruiting | Phase 2 | 32 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04005339 | NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer | active not recruiting | Phase 2 | 48 | Georgetown UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT04137107 | Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 220 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jan 26, 2026 | clinicaltrials |
| NCT04781192 | The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers | active not recruiting | Phase 1 / Phase 2 | 40 | University of Kansas Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04767984 | Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis | active not recruiting | Phase 2 | 42 | Northwestern UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03257163 | Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer | active not recruiting | Phase 2 | 40 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT00335816 | Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer | active not recruiting | Phase 2 | 248 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Jan 14, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04229459 | Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. | active not recruiting | Phase 2 | 12 | Baruch BrennerOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04539808 | NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer | active not recruiting | Phase 2 | 42 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04028167 | Induction FLOT With CROSS CRT for Esophageal Cancer | active not recruiting | Phase 2 | 40 | University of Colorado, DenverOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04241276 | A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer(STARPAC2) | active not recruiting | Phase 2 | 170 | Queen Mary University of LondonOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05504252 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin(METIMMOX-2) | active not recruiting | Phase 2 | 80 | University Hospital, AkershusOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03921684 | Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | active not recruiting | Phase 2 | 29 | Baruch BrennerOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03983993 | Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer(NIPAVect) | active not recruiting | Phase 2 | 26 | Emory UniversityOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT03991962 | Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma | active not recruiting | Phase 2 | 28 | Yale UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05902533 | REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation(REDEL) | active not recruiting | Phase 2 / Phase 3 | 33 | University of CincinnatiOTHER | 1 | Dec 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 24, 2026source: clinicaltrials